A Phase 3 interventional study of Nerinetide (NA-1) and Placebo in Acute Cerebral Ischemia, sponsored by NoNO Inc.. Completed at 4 sites in Canada. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-05-12.
Sponsored by NoNO Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 444 studies in Stroke with a site in Canada — 83 open to participants now, 99 under way, 13 of them phase 3. Stroke · Canada.
Among the 444 studies in Stroke with a site in Canada, this one is the 92nd largest by enrollment of the 374 interventional ones that give a count, is one of 25 that started in 2015, is one of 69 in phase 3, and was the 182nd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →83 of the 444 studies in Stroke with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 75+
Population Health Research Institute · Sites in Canada
Ages 18+
McMaster University · Sites in Canada
University of Calgary · Sites in Canada, Australia
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, United States, Japan
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 40 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
444 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 48 · Phase 3 78 · Phase 4 25
First in 1998; this study’s year is marked. 25 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 532 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 74 across the 374 interventional studies, 150 across the 67 observational. Of the 282 that completed or were terminated, 63 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 444 have an industry lead sponsor. The 10 most frequent:
NoNO Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
NoNO Inc. has 5 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
35 of the studies in Stroke with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06296082Phase 3Universiteit AntwerpenComparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity | 2026-12-30 |
| NCT07201974McGill UniversityVirtual Reality for Post-Stroke Gait Rehabilitation | 2026-11 |
| NCT05595668Nova Scotia Health AuthorityEngaging Mobile Prism Adaptation Treatment at Home | 2026-11 |
| NCT06828653Holland Bloorview Kids Rehabilitation HospitalComparing Digitally and Traditionally Made Ankle Foot Orthoses | 2026-12 |
Add all 35 to your calendar (.ics) → With an account.
Among the 444 studies in Stroke with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.
Nerinetide (NA-1) is being developed as an emergency drug aimed at reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.
The primary objective is to determine the efficacy of nerinetide in reducing global disability in patients with acute stroke. The secondary objectives are to determine the efficacy of nerinetide in reducing functional dependence, reducing mortality rate, reducing worsening of stroke, improving neurological outcome and improving activities of daily living.
The leading safety objectives are to determine the effect of administering a target dose of 2.60 mg/kg (up to a maximum dose of 270 mg) IV infusion of nerinetide within three hours of symptom onset by paramedics in the field on serious adverse events and 90-day mortality.
This trial is a multicenter, randomized, double-blind, placebo-controlled, single dose study initiated prehospital in the ambulance. It is being conducted using Emergency Medical Services (EMS) in Canada. Subjects with suspected acute stroke will be identified in the field by trained paramedics using the approved stroke protocol in use by the local EMS system, and further screened for eligibility and approval by an on-call trial physician. The paramedics will administer the study drug. Upon arrival at the emergency department, subjects will receive standard-of-care.
An Independent Data Monitoring Committee will perform safety reviews of the clinical data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.60 mg/kg of nerinetide (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
Drug: Nerinetide (NA-1)
Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
Drug: Placebo
Modified Rankin Scale (mRS) scale
The percentage of responders, using a sliding dichotomy on the mRS
Time frame: 90 days
mRS shift analysis
Shift to reduced functional dependence analyzed across the whole distribution of scores on the mRS
Time frame: 90 Days or the last rating
Mortality rate
A reduction in mortality as defined by event rate (proportion, expressed as a percentage)
Time frame: 90 Days
Worsening of stroke rate
A reduction in proportion of participants with worsening of stroke. Worsening of stroke is defined as progression, or hemorrhagic transformation, of the index stroke as documented in the study CRF that (i) is deemed life-threatening and/or (ii) results in increased disability as gauged by a ≥4 point increase from lowest NIHSS during hospitalization and/or (iii) results in death.
Time frame: 90 Days
National Institutes of Health Stroke Scale (NIHSS)
Proportion of subjects with good neurological outcome, as defined by a score of 0-1 on the NIHSS
Time frame: 90 Days or the last rating
Barthel Index
Proportion of subjects with functional independence in activities of daily living, as defined by a score of ≥ 95 on the Barthel Index
Time frame: 90 Days or the last rating
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2015 to primary completion in Mar 2023, 96 months.
Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 96 months is above that.
Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerinetide
NoNO Inc.